Zinc finger protein 852 (ZNF852)

Zinc finger protein 852 is a member of the classical C2H2 zinc finger protein family, a group that constitutes the largest family of transcription factors in the human genome[8][3][5]. These proteins commonly regulate gene expression by binding specific DNA sequences, and are involved in diverse functions including development, differentiation, and disease processes such as tumorigenesis[3][5][8]. ZNF852 is upregulated in gastric cancer cell lines and is essential for cancer cell proliferation, self-renewal, and resistance to the chemotherapeutic agent oxaliplatin[2][4][9]. Knockdown or loss of ZNF852 suppresses these cellular phenotypes and downregulates epidermal growth factor receptor (EGFR) in gastric cancer cells, suggesting that this protein is a potential therapeutic target for gastric cancer intervention[2]. There is currently no evidence of approved drugs directly targeting ZNF852 in clinical use, but it may mediate sensitivity to chemotherapeutics through regulatory pathways in cancer cells[2][4]. If further structure–function relationships or clinical roles become defined, additional molecular or therapeutic details may become available. No evidence of errors, name mismatches, or classification issues are present in the sources for this target.

Other names

ZNF852Putative zinc finger protein 852

Targeting ZNF852 may inhibit cancer cell proliferation and self-renewal and increase sensitivity of cancer cells to chemotherapeutic agents such as oxaliplatin